Meglumine antimoniate
From Wikipedia, the free encyclopedia
 |
|
|
Meglumine antimoniate
|
|
| Systematic (IUPAC) name | |
| Hydroxy-dioxostiborane; (2R,3R,4R,5S)-6-methylaminohexane-1,2,3,4,5-pentol | |
| Identifiers | |
| CAS number | |
| ATC code | P01 |
| PubChem | |
| Chemical data | |
| Formula | Variable |
| Mol. mass | Variable |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Meglumine antimoniate (or meglumine antimonate) is a medicine used for treating leishmaniasis. It is manufactured by Aventis and sold as Glucantime in France, and Glucantim in Italy. It belongs to a group of compounds known as the pentavalent antimonials. It is administered by intramuscular injection.
[edit] See also
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
|
|||||||||||||||||
